Dermira Inc (DERM) : Regents Of The University Of California added new position in Dermira Inc during the most recent quarter end. The investment management firm now holds 12,208 shares of Dermira Inc which is valued at $339,382 , the company said in a statement filed on May 10, 2016 with the SEC.Dermira Inc makes up approximately 1.42% of Regents Of The University Of California’s portfolio.
Other Hedge Funds, Including , Blackrock Investment Management boosted its stake in DERM in the latest quarter, The investment management firm added 161 additional shares and now holds a total of 78,407 shares of Dermira Inc which is valued at $2,179,715. Airain Ltd sold out all of its stake in DERM during the most recent quarter. The investment firm sold 9,299 shares of DERM which is valued $258,512.Numeric Investors boosted its stake in DERM in the latest quarter, The investment management firm added 72,177 additional shares and now holds a total of 223,884 shares of Dermira Inc which is valued at $5,283,662. Dermira Inc makes up approx 0.06% of Numeric Investors’s portfolio.Proshare Advisors reduced its stake in DERM by selling 2,277 shares or 8.65% in the most recent quarter. The Hedge Fund company now holds 24,045 shares of DERM which is valued at $567,462. Dermira Inc makes up approx 0.01% of Proshare Advisors’s portfolio.Schwab Charles Investment Management Inc boosted its stake in DERM in the latest quarter, The investment management firm added 969 additional shares and now holds a total of 48,420 shares of Dermira Inc which is valued at $1,142,712.
Dermira Inc opened for trading at $28.5 and hit $30.31 on the upside on Monday, eventually ending the session at $30.22, with a gain of 8.71% or 2.42 points. The heightened volatility saw the trading volume jump to 4,28,576 shares. Company has a market cap of $907 M.
Many Wall Street Analysts have commented on Dermira Inc. Company shares were Reiterated by Needham on May 11, 2016 to “Buy”, Firm has raised the Price Target to $ 42 from a previous price target of $38 .
Dermira Inc. is a specialty biopharmaceutical company focused on bringing medical dermatology products to dermatologists and their patients. The Company’s portfolio of five product candidates includes three late-stage product candidates. The late-stage product candidates are Cimzia (certolizumab pegol) which the Company is developing in collaboration with UCB Pharma S.A. (UCB) DRM04 and DRM01. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor or TNF inhibitor that is approved and marketed by UCB for the treatment of numerous inflammatory diseases spanning multiple medical specialties. DRM04 is a topical small-molecule anticholinergic product the Company is developing for the treatment of hyperhidrosis or excessive sweating. DRM01 is a topical small-molecule sebum inhibitor the Company is developing for the treatment of acne.